NBIX in “America Imports the World's Drug Prices”
Neurocrine Biosciences, Inc.
Neurocrine's earnings are concentrated in high-value branded therapies such as Ingrezza, making it exposed to reference-pricing pressure on US prices and future international launch strategy.
NBIX impact map — “America Imports the World's Drug Prices”
How this story travels from the headline to NBIX’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading NBIX impact map…
Price history, marked with story events
Oct 7, 2019 – Oct 5, 2020 · 252 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
America Imports the World's Drug Prices
US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
BEAR side — Neurocrine's earnings are concentrated in high-value branded therapies such as Ingrezza, making it exposed to reference-pricing pressure on US prices and future international launch strategy.
Read the full America Imports the World's Drug Prices storyBull side
1 story- The Patent Cliff Sparks a Biotech Land Grab
NBIX in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
A profitable neurology franchise and de-risked clinical pipeline give Neurocrine the commercial validation sought by acquirers needing near-term revenue.
Bear side
1 story- Viewing
NBIX in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Neurocrine's earnings are concentrated in high-value branded therapies such as Ingrezza, making it exposed to reference-pricing pressure on US prices and future international launch strategy.